Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Piramal Pharma Ltd

PPLPHARMA.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: STRONG BUY

Last Close

$2.17

▼ -2.84%

Market Cap $2.87B · Vol 11.44M

Key Metrics

P/E Ratio

N/A

FWD: 81.97

Market Cap

$2.87B

Mid Cap

Div Yield

0.00%

Annual dividend

EPS Growth

+266.00%

YoY

RSI (14)

69.84

Momentum

Beta

1.44

vs Market

52W High

$2.29

8.93% below

52W Low

$1.39

53.59% above

Volume

11.44M

Avg 7.29M

P/B

2.22

Price-to-book

ROE

-1.59%

Return on equity

Free Float

45.47%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Piramal Pharma Ltd (PPLPHARMA.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PPLPHARMA.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.39%

+20.19%

+18.38%

+24.52%

YTD

+19.99%

+8.74%

+86.61%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$949.00M
Net Income	$-34,875,932.00
Revenue Growth (YoY)	+17.39%
Gross Margin	51.26%
Operating Margin	2.83%
Net Profit Margin	-3.68%
ROE	-1.59%
ROA · ROIC	-1.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	81.97
PEG Ratio	N/A
P/S	2.04
P/B	2.22
P/FCF	36.22
EPS Growth	+266.00%
Outstanding Shares	1.33B

Technical Indicators

50-Day SMA	$1.89
200-Day SMA	$1.79
RSI (14)	69.84
Beta	1.44
52-Week High	$2.29
52-Week Low	$1.39

Volume Today	11.44M
Avg Daily Volume (30D)	7.29M
Relative Volume	1.57x
Volatility (10D)	25.05
Volatility (30D)	33.96
Free Float	45.47%

Analyst Consensus

STRONG BUY

Current Price $2.17

Mean Target $2.46

52W Low$1.39 52W High$2.29

Current

Target

$1.39 $2.29

Current Analyst target

+13.60% upside potential · 11 analysts

Identifiers

ExchangeNSE India

FIGIBBG00XC7SWM3

ISININE0DK501011

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 29, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.